Icosapent Ethyl
Amarin Pharmaceutical
[]
#respect-epa secondary prevention #epa 1800mg/d non mineral oil controls shows non significant p=.05 trend for benefit for #epa with 21% in primary outcomes, underpowered w ~ 2500 pts(not enough cv events) in afib &amp; gi symptoms but no bleeding #aha22 
AssistProfessor #cardiologist #SoMe #editor @CircOutcomes & @JournalASEcho #BOD @ase360 #ACCWIC @PittHealthSci #MedHumanities @ColumbiaMed @NUFeinbergMed